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BIOMEDICAL RESEARCH IN FRANCE AND BRAZIL: 
AN ANALYSIS OF SIGNIFICANT DIFFERENCES AND 
ETHICAL ISSUES
At first sight, Brazil and France seem pretty distant from one another, but 
on the map, they are not separated by the Atlantic Ocean, but by the Oyapock 
River, located between the state of Amapa and French Guiana (French overseas 
department), creating a 730 km long international border. If the distance does 
exist, it is very different when we finely analyze some similarities in the field of 
biomedical research.
France is the biggest country of Western Europe and covers 1/5 of the European 
Union. Apart from Metropolitan France, the country contains overseas territories, 
remnants of its colonial past. Over the centuries, France has known several political 
systems, from Ancient History to the current Republic. According to Ernest Renan, 
the French nation is more an ideology than a reality, primarily based on “the desire 
of living together and the wish to highlight our legacy”(1). The tragic attacks of 
November 2015 and all the reactions over the next days illustrate this.
Brazil, discovered by the Portuguese explorer Pedro Alvares during the 16th 
century, is established on half of South America and is about 16 times bigger 
than France. This giant does not look to the past but is always moving forward. 
The concept of nation is really strong throughout the country, as shown by the 
enthusiasm of soccer players wearing the national auriverde jersey and the National 
Team supporters. Furthermore, they possess a strong culture of entrepreneurship 
defined by Stefan Zweig as the legacy of the early colonial era(2).
Biomedical research is a human activity which aims to give expected solutions, 
and sometimes unexpected ones too, to a major and insoluble problem at a given 
time. This research is based on knowledge and will question it with a scientific 
approach, spread between what is known today and what will be known tomorrow. 
Ideally, the point of getting new knowledge is to improve a group of people or the 
entire population’s health. The researcher is a creator of knowledge but is also a 
pioneer, what imposes an ethical responsibility. For the last 20 years, the way how 
biomedical research is led has changed with the definition of “good clinical practice”. 
The globalization of the biomedical research is explained by the fact that we have 
made many improvements so far but we always need more and more patients to 
prove the superiority of a treatment to another. Many patents about “blockbusters 
treatments” expire soon, so the pharmaceutical industry speeds up to discover 
new ones to replace them, which explains the multiplication of clinical trials. The 
pharmaceutical industry and the emerging markets share common interests, which 
lead them to work together, increasing the phenomenon of globalization.
The good clinical practice refers to standards shared by Europe, North 
America, Japan and Australia, about international ethical and scientific quality 
defining the conception, the conduct, the registration and the presentation of data 
during trials involving human beings. Emerging markets are not obliged to follow 
these standards, what implies that part of the modalities can be dissimulated. The 
International Conference on Harmonisation(3) has elaborated recommendations 
related to the research and the development of new medications which clearly aim 
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to limit human, animal and material resources to decrease 
the time for the trials.
The Brazilian health law respects these international 
standards and is the most advanced in Latin America along 
with the Argentinian and Mexican systems. In addition, 
many Brazilian doctors have studied overseas and respect 
these rules. However, if consensuses on theoretical notions 
about bioethics exist, there are still differences on the way 
research policies are applied. If respecting all international 
standards about ethics (Declaration of Helsinki 1964, 
Belmont Report 1978, International Ethical Guidelines for 
Biomedical Research Involving Human Subjects and the 
Resolution of the National Health Council CNS 196/96) 
is required by every Brazilian scientific review and the 
National Commission for Ethics in Research, it is surprising 
that this resolution, which aimed to protect the patients, the 
institutions and the country, has been recently (12/12/12) 
dismissed(4). It is easy to acknowledge a whole scientific 
community of a country a dignity of principle, but it is 
harder to define the modalities of its implementation on 
the border of life (birth and death) when these nations have 
fundamental cultural, economical, historical and societal 
differences. The following examples illustrate the various 
ethical challenges.
Geopolitics
Brazil has many advantages favoring the development 
of biomedical research on its territory. Its situation in the 
Southern hemisphere with inverted seasons compared to 
Europe allows trials all along the year. Its proximity with 
the US and Canadian pharmaceutical companies, compared 
to Asia, is more convenient for logistics. The incidence 
of many diseases is pretty similar to Europe and North 
America with a high incidence of cardiovascular diseases 
(42% of men aged 65 or older), type 2 diabetes (6.9 million 
adults), breast and prostate cancer. The Agência Nacional 
de Vigilância Sanitária – ANVISA (Brazil’s National Health 
Surveillance Agency) registers every clinical trial, and 
shows that breast cancer and type 2 diabetes are the two 
most studied pathologies with respectively 20.5% and 26%. 
Those data highlight the problem of neglected or “orphan” 
diseases for pharmaceutical companies that have a local 
impact on mortality or economy, such as dengue fever or 
Chagas disease(5).
Economy
Brazil has had a 4% continuing economic growth for 
the last ten years. This economic development has been 
seriously reduced since 2011. Its prime mover is its domestic 
consumption – with 200 million inhabitants – coupled 
with advantages of its huge vegetal and mineral resources. 
Nevertheless, Brazil is ranked 120 out of 189 by the World 
Bank for the ease of entrepreneurship. In biomedical 
research, countries are rated regarding their attractiveness 
from 1 to 10. Brazil is scored 5.26 – just behind China(6).
According to Goldman Sachs’ economist Jim O’Neill(7), 
Brazil is one of the five BRICS countries with Russia, India, 
China and South Africa. Those countries represent the five 
major emerging national economies. Their markets should 
grow until the sum of their GDP reaches the one of the G6 
countries around 2040 (Japan, USA, UK, France, Germany, 
Italy). This notion helps the investigators/investors to find 
the countries which offer the best opportunities. Brazil 
is definitely one of those; its Human Development Index 
(HDI), a composite score of life expectancy, education, 
and income per capita indicators is 79/187 versus 20/187 
for France. This index has been created to highlight that 
people and their abilities should be the main indicators used 
to evaluate the potential of growth for a country and not 
only economic criteria. It can be used to question political 
choices. The reasons why Brazil is often solicited for 
clinical trials are explained by the following elements. An 
important growth of its pharmaceutical market over the last 
years, a highly urbanized population with an easy access to 
medications due to a generous government health program, 
important infrastructures in large metropolises (São Paulo, 
Rio de Janeiro) gathering the major part of the resources, 
a high relevance in clinical expertise, an important part 
of the population is treatment naive, which seduces the 
pharmaceutical industry, reasonable costs for research with 
a low-constraining regulation, an eased patient recruitment, 
and a surprising transdisciplinarity(8).
Culture
The French “exception culturelle” (cultural exception) 
designates past or actual French specificities compared to 
other countries in the cultural field. This definition implies 
pride, pretentiousness and the feeling that French culture is 
superior to others. This cultural diversity is closely related to 
the organization of the society. In France, national collective 
solidarity is highly developed to facilitate the access to the 
health system. Some other societies, like Brazil, allow more 
importance to the familial or local communities and a low 
national investment in the health system. In this way, the 
decision for a woman to participate in a clinical trial will be 
made by a man of her family, either her husband, her father 
or her brother and not by herself. Those cultural differences 
between our two countries explain why clinical research on 
the embryo is forbidden in France and allowed in Brazil 
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since the Biosecurity law (2005). On the other hand, 
abortion is forbidden in Brazil and is allowed in France. 
The excess of some investigators associated with 
the pressure from clinical trials leaders led those “body 
hunters” to get established in developing markets, losing 
the perspective of the final objective of any biomedical 
research, which is supposed to be the improvement of the 
conditions of life for the whole human community. The 
complexity of the actual context for biomedical research 
– multiple financial sources, multicenter trials, variable 
regulatory constraints, risky trials – must alert permanently 
the researcher so he will be able to apply an ethics of 
responsibilities more than convictions, as theorized by 
German sociologist Weber(9). 
Thanks to Pierre Keribin for the translation of the 
editorial
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  Table 1 - Comparison between France and Brazil based on 12 criteria.
Criteria France Brazil
Population and density (Pop. per km2) 66 million; 121 201 million; 24
Urban population 79.3 % 85.4 %
Inflation rate 0.5 % 5.5 %
Unemployment rate 10.5 % 5.8 %
Human Development Index 20/187 79/187
Language French Portugese
Child mortality 3.34 ‰ 19,83 ‰
Life expectancy 81.75 73.53
Medical Doctors per 1000 inhabitants 3.19 1.9
Prevalence of obesity 16 % 16.2 %
Literacy rate 99 % 88.6 %
World rank for scientific publications 6th 13th
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